Oncology – Gastrointestinal
M-A | Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer
15 Mar, 2023 | 14:52h | UTCRelated:
Colorectal cancer statistics in the US, 2023
6 Mar, 2023 | 14:02h | UTCColorectal cancer statistics, 2023 – CA: A Cancer Journal for Clinicians
ACG Guideline | Diagnosis and management of biliary strictures
3 Mar, 2023 | 14:13h | UTC
Study suggests there is little added value from follow-up pelvic CT after treatment of hepatocellular carcinoma
23 Feb, 2023 | 13:39h | UTCSummary: The study investigated the added value of pelvic coverage at follow-up liver CT in detecting pelvic metastasis or incidental tumors in patients treated for hepatocellular carcinoma (HCC). The study found that the incidence of isolated pelvic metastasis or incidental pelvic tumor was low in patients treated for HCC. The cumulative rates of isolated pelvic metastasis and incidental pelvic tumor were 1.4% and 0.5%, respectively, at 3 years. Only baseline T stage was associated with an increased risk of isolated pelvic metastasis. The study concludes that excluding the pelvic scan can reduce radiation dose and decrease the workload for radiologists. However, the study also had limitations, such as being retrospective and single-center. Therefore, more research is necessary to study the optimal scanning strategy for the pelvis and the effect of pelvic CT coverage on survival in patients with HCC.
Article: Added Value of Pelvic CT after Treatment of HCC – Radiology
RCT | Laparoscopic proximal gastrectomy with double-tract reconstruction vs. total gastrectomy in upper-third early gastric cancer
23 Feb, 2023 | 13:29h | UTCSummary: This randomized trial examined whether laparoscopic proximal gastrectomy with double-tract reconstruction (LPG-DTR) is a superior surgical treatment compared to laparoscopic total gastrectomy (LTG) for patients with early gastric cancer (GC) in the upper third of the stomach. The study found that LPG-DTR resulted in significantly decreased amounts of vitamin B12 supplementation, but no significant difference in hemoglobin change compared to LTG. The study also found no difference in complication rates or overall and disease-free survival rates between the two groups. The study suggests that LPG-DTR may be a function-preserving procedure for the treatment of patients with upper-third early GC.
Commentary on Twitter
RCT: Proximal gastrectomy with double tract reconstruction had an advantage of less vitamin B12 supplementation than total gastrectomy similar complication rates and survival in patients with upper third early gastric cancer. https://t.co/tdAktJxkpL pic.twitter.com/5miUbb9Ia6
— JAMA Network Open (@JAMANetworkOpen) February 15, 2023
Cohort Study | Risk and timing of venous thromboembolism in patients with gastrointestinal cancer
23 Feb, 2023 | 13:08h | UTC
RCT | Pembrolizumab vs. placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma
16 Feb, 2023 | 14:40h | UTCCommentary: KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC – The ASCO Post
Guideline | Barrett’s esophagus and stage 1 esophageal adenocarcinoma: monitoring and management
13 Feb, 2023 | 12:49h | UTC
Opinion | Interpreting the results from the first randomized controlled trial of colonoscopy: does it save lives?
10 Feb, 2023 | 13:54h | UTCOriginal Study: RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
RCT | Effects of the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer
9 Feb, 2023 | 13:45h | UTC
Commentary on Twitter
Single centre #RCT of surgery for T3/4 N+ #rectalcancer before or after 8 weeks of CRT
???350 patients
⚖️no difference locoregional recurrence
Distant mets more common in delayed group at 5yrs
DFS and OS similar#some4surgery @SEIQuirurgica @asgbi https://t.co/4evsKNKKK1 pic.twitter.com/CxI0GJdG56— BJS Open (@BjsOpen) October 24, 2022
RCT | First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma
3 Feb, 2023 | 14:02h | UTC
M-A | Treatment- and immune-related AEs of checkpoint inhibitors in esophageal or gastroesophageal junction cancer
3 Feb, 2023 | 13:55h | UTC
M-A | Major complications and mortality after resection of intrahepatic cholangiocarcinoma
3 Feb, 2023 | 13:43h | UTC
M-A | Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer
2 Feb, 2023 | 14:36h | UTC
M-A | Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma
31 Jan, 2023 | 13:42h | UTC
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
M-A | Proximal gastrectomy with double-tract-reconstruction vs. total gastrectomy in gastric and gastroesophageal junction cancer patients
27 Jan, 2023 | 11:54h | UTC
RCT | Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion
26 Jan, 2023 | 12:03h | UTC
RCT | Preoperative chemotherapy reduced recurrence in operable colon cancer
25 Jan, 2023 | 11:29h | UTCEditorial: FOxTROT: Are We Ready to Dance? – Journal of Clinical Oncology
News Release: Chemotherapy before surgery cuts risk of colon cancer returning, trial finds – Cancer Research UK
Commentary: New treatment strategy cuts risk of bowel cancer returning by 28% – The Guardian
Commentary from one of the authors on Twitter (thread – click for more)
???Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A ? (1/14)#crcsmhttps://t.co/y1hU6qWdXF— Jenny Seligmann (@JenSeligmann) January 20, 2023
Cohort Study | Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120 000 repeated screening colonoscopies
23 Jan, 2023 | 13:36h | UTCCommentaries:
Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay
Commentary on Twitter
Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ
— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023
RCT | Adjuvant S-1 compared with observation in resected biliary tract cancer
23 Jan, 2023 | 13:24h | UTCAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023
Single-arm phase 2 study | Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
23 Jan, 2023 | 13:22h | UTCFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg
— NEJM (@NEJM) January 19, 2023
Cohort Study | Hemicolectomy vs. appendectomy for patients with appendiceal neuroendocrine tumors 1–2 cm in size
23 Jan, 2023 | 13:21h | UTCHemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors – The ASCO Post
MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning
20 Jan, 2023 | 14:34h | UTC
Single-arm phase 1-2 study | Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer
20 Jan, 2023 | 14:31h | UTCSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months. https://t.co/BUepIWvx65 pic.twitter.com/i1kugfC6Nq
— NEJM (@NEJM) December 21, 2022